180 related articles for article (PubMed ID: 21450814)
1. Interactions of human complement with virus particles containing the Nipah virus glycoproteins.
Johnson JB; Aguilar HC; Lee B; Parks GD
J Virol; 2011 Jun; 85(12):5940-8. PubMed ID: 21450814
[TBL] [Abstract][Full Text] [Related]
2. A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F).
Aguilar HC; Ataman ZA; Aspericueta V; Fang AQ; Stroud M; Negrete OA; Kammerer RA; Lee B
J Biol Chem; 2009 Jan; 284(3):1628-35. PubMed ID: 19019819
[TBL] [Abstract][Full Text] [Related]
3. Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo.
Palomares K; Vigant F; Van Handel B; Pernet O; Chikere K; Hong P; Sherman SP; Patterson M; An DS; Lowry WE; Mikkola HK; Morizono K; Pyle AD; Lee B
J Virol; 2013 Feb; 87(4):2094-108. PubMed ID: 23192877
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage.
Negrete OA; Chu D; Aguilar HC; Lee B
J Virol; 2007 Oct; 81(19):10804-14. PubMed ID: 17652392
[TBL] [Abstract][Full Text] [Related]
5. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.
DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H
Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094
[TBL] [Abstract][Full Text] [Related]
6. Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody.
Bae SE; Kim SS; Moon ST; Cho YD; Lee H; Lee JY; Shin HY; Lee HJ; Kim YB
Biochem Biophys Res Commun; 2019 Jun; 513(4):781-786. PubMed ID: 30995971
[TBL] [Abstract][Full Text] [Related]
7. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.
Zhu Z; Dimitrov AS; Bossart KN; Crameri G; Bishop KA; Choudhry V; Mungall BA; Feng YR; Choudhary A; Zhang MY; Feng Y; Wang LF; Xiao X; Eaton BT; Broder CC; Dimitrov DS
J Virol; 2006 Jan; 80(2):891-9. PubMed ID: 16378991
[TBL] [Abstract][Full Text] [Related]
8. Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems.
Bossart KN; McEachern JA; Hickey AC; Choudhry V; Dimitrov DS; Eaton BT; Wang LF
J Virol Methods; 2007 Jun; 142(1-2):29-40. PubMed ID: 17292974
[TBL] [Abstract][Full Text] [Related]
9. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
10. Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase.
Kaku Y; Noguchi A; Marsh GA; Barr JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang LF
J Virol Methods; 2012 Jan; 179(1):226-32. PubMed ID: 22115786
[TBL] [Abstract][Full Text] [Related]
11. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus.
Negrete OA; Levroney EL; Aguilar HC; Bertolotti-Ciarlet A; Nazarian R; Tajyar S; Lee B
Nature; 2005 Jul; 436(7049):401-5. PubMed ID: 16007075
[TBL] [Abstract][Full Text] [Related]
12. Development of a neutralization assay for Nipah virus using pseudotype particles.
Tamin A; Harcourt BH; Lo MK; Roth JA; Wolf MC; Lee B; Weingartl H; Audonnet JC; Bellini WJ; Rota PA
J Virol Methods; 2009 Sep; 160(1-2):1-6. PubMed ID: 19559943
[TBL] [Abstract][Full Text] [Related]
13. Triggering of the newcastle disease virus fusion protein by a chimeric attachment protein that binds to Nipah virus receptors.
Mirza AM; Aguilar HC; Zhu Q; Mahon PJ; Rota PA; Lee B; Iorio RM
J Biol Chem; 2011 May; 286(20):17851-60. PubMed ID: 21460213
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the G-H loop region of ephrin-B2 can enhance Nipah virus binding and infection.
Yuan J; Marsh G; Khetawat D; Broder CC; Wang LF; Shi Z
J Gen Virol; 2011 Sep; 92(Pt 9):2142-2152. PubMed ID: 21632558
[TBL] [Abstract][Full Text] [Related]
15. A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b.
Johnson JB; Borisevich V; Rockx B; Parks GD
J Virol; 2015 Jan; 89(2):989-98. PubMed ID: 25355897
[TBL] [Abstract][Full Text] [Related]
16. [Study on the DNA immunogenicity of fusion and attachment glycoproteins of Nipah virus].
Wang XJ; Ge JY; Wang QH; Hu S; Lin XM; Bu ZG
Bing Du Xue Bao; 2008 Jan; 24(1):47-52. PubMed ID: 18320822
[TBL] [Abstract][Full Text] [Related]
17. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
[TBL] [Abstract][Full Text] [Related]
18. Evidence of a potential receptor-binding site on the Nipah virus G protein (NiV-G): identification of globular head residues with a role in fusion promotion and their localization on an NiV-G structural model.
Guillaume V; Aslan H; Ainouze M; Guerbois M; Wild TF; Buckland R; Langedijk JP
J Virol; 2006 Aug; 80(15):7546-54. PubMed ID: 16840334
[TBL] [Abstract][Full Text] [Related]
19. Multiple Strategies Reveal a Bidentate Interaction between the Nipah Virus Attachment and Fusion Glycoproteins.
Stone JA; Vemulapati BM; Bradel-Tretheway B; Aguilar HC
J Virol; 2016 Dec; 90(23):10762-10773. PubMed ID: 27654290
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization.
Johnson JB; Schmitt AP; Parks GD
J Virol; 2013 Aug; 87(16):9250-9. PubMed ID: 23785199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
